Articles related to LGBTQIA+ MEDICINE

In this study, of the 118 transgender and gender nonbinary (TGNB) patients, one-third of participants reported misgendering (being addressed in the dental environment using the wrong name and pronouns). Although refusal of oral health care was uncommon in our sample of TGNB participants, more than half believed that their regular source of oral health care was unable to provide gender-appropriate care. Avoidance owing to gender identity was found to be substantially related to self-reported unsatisfactory dental health. Gender insensitivity, awkward interactions, avoidance of care, and a lack of gender-affirming practitioners were all common themes un participants’ oral health care experiences.

All agree that the well-being of the patient is paramount. But how to find that in the midst of so much hostility and criticism? When the evidence base is weak or disputed, other factors must be weighed, such as how invasive is the recommended intervention.

The question of whether, when, and how children and adolescents with gender dysphoria should be treated medically or surgically is contentious. Gender dysphoria in the United States is being treated with “gender affirming care,” which may include gonadotrophin releasing hormone analogues (GnRHa) to suppress puberty, oestrogen or testosterone to promote secondary sex characteristics, and surgical removal or augmentation of breasts, genitals, or other physical features. At the same time, several European countries have issued guidelines limiting medical intervention in minors and emphasizing psychological care. There is little doubt in the medical community that children in distress require care, but there are concerns about the rapid widespread adoption of interventions and calls for rigorous scientific review from all corners.

Sunlenca (lenacapavir), which comes in 300 mg tablets and a 463.5 mg/1.5 mL injection, provides doctors with a long-needed twice-yearly option for patients with complicated past treatment histories who would otherwise have few treatment options.

The American Journal of Psychiatry presents this review of the most compelling articles that were covered in 2022: The Molecular and Cellular Alterations That Underpin Psychiatric Illnesses Shared and Distinct Neurobiological Mechanisms of PTSD Cognitive Deficits in Long-Term Cannabis Users Longitudinal Outcomes of Duration of Untreated Psychosis Accelerating TMS in the Treatment of Depression Infant Brain Development, Fragile X Syndrome, and Autism Spectrum Disorder Combining Computational Modeling and Postmortem Human Brain Studies to Uncover Synaptic Variability Contributions to Cortical Gamma Oscillation From the AJP Residents’ Journal: Identity and Stigma

A trio of posters look at clinical effectiveness fostemsavir for multidrug-resistant patients, real-world efficacy of the dolutegravir/lamivudine combination as a switch strategy, and a newer drug in the pipeline, islatravir prodrug BRII-732.